Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients With Solid Tumors

Trial Profile

A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Gatipotuzumab (Primary) ; Tomuzotuximab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms GATTO
  • Sponsors Glycotope
  • Most Recent Events

    • 05 Jun 2018 According to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology, as of January 2018, 2 patients have been treated
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 22 Dec 2017 According to a Glycotope media release, the company has enrolled the first patient in its international GATTO study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top